Logo
Eloquence Sub Q with Lidocaine

Eloquence Sub Q with Lidocaine

Eloquence

Dermal filler – hyaluronic acid injectable
  • Eloquence fillers, including Sub Q, are described by multiple European distributors and official brochures as CE Marked Medical Class II hyaluronic acid dermal fillers.
  • Manufactured by Jetema, a Korean pharmaceutical and aesthetic company that produces other globally distributed HA filler brands such as Regenovue and e.p.t.q., under stringent quality standards.
  • Produced in accordance with The IX Essential Process criteria for HA fillers, including high Purity HA, high viscoelasticity, low endotoxin content (<0.1 EU/ml), optimised cross Linking, physiological pH/osmolarity and controlled injection pressure.
  • Incorporates ZEEP Technology (Zero Endotoxin & BDDE Entire Process) and advanced manufacturing processes aimed at reducing residual BDDE and endotoxins while maintaining product performance.
  • Manufacturing and quality management systems are aligned with internationally recognised medical device quality standards (e.g. ISO 13485 Based systems) as reflected in distributor technical documentation and regulatory statements.
Subcutaneous / deep hyaluronic acid dermal filler with lidocaine for volumisation and contouring

Description

Eloquence Sub-Q with Lidocaine is the thickest, most robust hyaluronic acid dermal filler in the Eloquence range. Manufactured by the Korean company Jetema, it is a highly viscous, cohesive, cross-linked HA gel with 24 mg/ml hyaluronic acid and 0.3% (3 mg/ml) lidocaine, designed for the correction of very deep wrinkles and folds and for extensive volumisation and contouring of the cheeks, chin, jawline, forehead and nose. It can also be used to plump, volumise and define the lips in appropriately selected patients. The dense, high-elasticity gel structure enables strong lifting capacity, structural support and a volumised yet natural-looking result that is long-lasting, with many sources indicating results can last from about 6 up to 18 months, and The Crystal Pharmacy describing effects of treatment for up to 18 months when used correctly.

Bnefits

  • Thickest and most robust formulation in the Eloquence range, ideal for deep wrinkles and structural volumisation.
  • High-viscosity, cohesive gel provides strong lifting capacity and long-lasting facial contouring.
  • Suitable for augmentation and sculpting of cheeks, chin, jawline, forehead and nose to enhance and structure natural features.
  • Can also be used to plump, volumise and define lips where a denser, more structural filler is indicated.
  • Contains 0.3% lidocaine to reduce injection pain and improve patient comfort throughout treatment.
  • High-elasticity hyaluronic acid with a dense structure supports natural-looking yet substantial volume and definition.
  • 24 mg/ml HA concentration delivers powerful volumising and hydrating effects.
  • Low endotoxin content (<0.1 EU/ml) and optimised cross-linking technology are designed to minimise swelling and reduce the risk of adverse reactions.
  • CE-marked Medical Class II dermal filler produced according to stringent HA filler quality and safety standards.

Indications

  • Correction of very deep facial wrinkles and folds, including deep nasolabial folds.
  • Volumetric augmentation and contouring of the cheeks and cheekbones.
  • Chin augmentation and reshaping to improve facial profile and harmony.
  • Jawline definition and contouring for enhanced lower-face structure.
  • Non-surgical nose reshaping (nasal dorsum and tip refinement) in experienced hands.
  • Forehead and facial contour volumetrics where a high-viscosity, lifting filler is required.
  • Lip plumping, volumisation and definition for patients who require a denser, long-lasting filler, as judged appropriate by the treating clinician.
  • General facial contouring and facial volumetrics to restore or enhance structural support in deep tissues.

Composition

  • Cross-linked sodium hyaluronate (hyaluronic acid) 24 mg/ml (non-animal origin).
  • Lidocaine hydrochloride 3 mg/ml (0.3%) as a local anaesthetic.
  • Phosphate-buffered saline (pH approximately 7.0) to ensure product stability and physiological compatibility.
  • Endotoxin content less than 0.1 EU/ml according to manufacturer and distributor technical information for Eloquence fillers.
  • Residual BDDE (cross-linking agent) minimised through ZEEP (Zero Endotoxin & BDDE Entire Process) and other optimised manufacturing steps.

Formulation

  • Monophasic, cross-linked hyaluronic acid gel with lidocaine for injectable implantation.
  • Hyaluronic acid concentration: 24 mg/ml.
  • Lidocaine concentration: 3 mg/ml (0.3%).
  • Syringe volume: typically supplied as a pre-filled 1.1 ml sterile syringe (some distributors list 1.0 ml; 1.1 ml is most commonly specified in European technical leaflets).
  • Needles included per box (commonly): 1 x 25G and 1 x 27G sterile needles.
  • High-viscosity, highly cohesive gel specifically engineered for deep dermal and subcutaneous injections.
  • Medical Class II CE-marked hyaluronic acid dermal filler.

Packaging

  • One single-use, pre-filled glass syringe containing approximately 1.1 ml of cross-linked hyaluronic acid gel with lidocaine.
  • Each unit box typically contains 1 sterile pre-filled syringe and 2 sterile needles (commonly 1 x 25G and 1 x 27G) in a blister tray.
  • Outer carton printed with product name (Eloquence Sub-Q), volume, batch number, expiry date and CE marking.
  • Sterile, pyrogen-free medical device intended for single-patient use by trained professionals only.

Usage

  • For professional use only – Eloquence Sub-Q with Lidocaine must be administered exclusively by suitably trained and qualified medical or aesthetic practitioners with a thorough understanding of facial anatomy and filler complication management.
  • Perform a full consultation, including medical history, assessment of indications and contraindications, and informed consent before treatment; pre-treatment photographs are recommended.
  • Cleanse and disinfect the treatment area according to clinic protocol. Additional topical anaesthetic may be used if desired, recognising that the product already contains lidocaine.
  • Eloquence Sub-Q is generally injected into the deep dermis, subcutaneous tissue or supraperiosteal plane depending on the area and indication. Use appropriate injection techniques (e.g. linear threading, depot, fanning, bolus) with needle or cannula as per training and clinical judgement.
  • Inject slowly with minimal pressure, regularly monitoring tissue response and patient feedback; aspirate according to clinic protocol and avoid intravascular injection by using safe techniques and continuous observation.
  • Build volume gradually, avoiding overcorrection, especially in high-risk areas such as the nose, glabella and lips.
  • After injection, gently massage and mould the product as needed to achieve smooth contours and symmetry, taking care not to displace the filler from the desired plane.
  • Provide written and verbal aftercare instructions, including advice to avoid extreme heat or cold, vigorous exercise, pressure or massage on treated areas, and makeup application for the period recommended by the practitioner (often 12–24 hours).
  • Inform patients of common side effects (e.g. swelling, bruising) and educate them on signs of serious complications such as severe pain, blanching, mottling, dusky discolouration or visual disturbances; advise immediate contact or emergency review if such symptoms occur.
  • Any unused product, opened syringes and needles must not be re-used and must be disposed of as clinical sharps waste in accordance with local regulations.

Contraindications

  • Known hypersensitivity or allergy to hyaluronic acid, lidocaine or other amide-type local anaesthetics, or to any of the excipients.
  • History of severe allergic reactions or anaphylaxis to injectable products unless thoroughly evaluated and managed by an experienced clinician.
  • Presence of active skin infection, inflammation or lesions (e.g. acne, herpes simplex) at or close to the intended injection site.
  • Autoimmune diseases, immunodeficiency or other significant systemic conditions where dermal filler use is deemed inappropriate by the treating physician.
  • Bleeding disorders, significant coagulation abnormalities or current use of high-dose anticoagulant or antiplatelet therapy where risks outweigh benefits and cannot be adequately managed.
  • Pregnancy and breastfeeding – hyaluronic acid dermal fillers containing lidocaine are generally not recommended due to limited safety data.
  • History of hypertrophic scarring or keloid formation, or major connective tissue disorders, unless carefully evaluated and deemed low risk by a specialist.
  • Previous implantation of permanent or certain semi-permanent fillers in the same area, where there may be a risk of interaction, nodularity or unpredictable results.
  • Any medical condition, medication or circumstance that, in the judgement of the prescribing clinician, makes dermal filler injection unsuitable or unsafe for the patient.

Adverse Effects

  • Common, generally transient injection-site reactions such as redness (erythema), swelling, tenderness, pain, itching, bruising and slight discolouration at the treatment site; these usually resolve within a few days.
  • Temporary firmness, palpable lumps or irregularities in the treated area, particularly if the gel is not evenly distributed; often manageable with massage or, if persistent, with hyaluronidase in the hands of a trained clinician.
  • Short-term feeling of tightness or pressure due to volumisation and local tissue expansion.
  • Local hypersensitivity reactions including prolonged redness, swelling or induration; these may require medical assessment and treatment.
  • Infection at the injection site if aseptic technique is inadequate or in predisposed patients, presenting with warmth, pain, erythema and swelling and requiring medical treatment.
  • Vascular compromise or occlusion if the filler is inadvertently injected intravascularly or causes external compression of a vessel; signs can include severe or disproportionate pain, blanching, mottling or dusky skin discolouration and, in severe cases, tissue necrosis. This is a medical emergency and must be managed immediately according to established filler complication protocols (e.g. prompt use of hyaluronidase and adjunctive measures).
  • Very rare but serious events reported for HA fillers in general, such as visual disturbances, visual loss, stroke or neurological symptoms secondary to embolic vascular occlusion; prevention, rapid recognition and emergency management training are essential for practitioners.
  • Delayed inflammatory reactions, granuloma formation or biofilm-related complications, which are rare but may occur and require pharmacologic and/or procedural intervention.
  • Transient numbness or altered sensation associated with lidocaine or injection trauma, typically resolving spontaneously.

Storage Conditions

  • Store at the temperature range specified by the manufacturer (commonly between 2 °C and 25 °C) and do not freeze.
  • Keep the syringe in its original blister and carton until use to protect it from light and contamination.
  • Do not use the product after the expiry date printed on the packaging.
  • Do not use if the blister pack, syringe or needle packaging is damaged, opened or shows any sign of compromise.
  • Store out of the reach and sight of children and unauthorised persons, in accordance with local regulations for medical devices.
  • Dispose of any used syringes, needles and unused remnants as clinical sharps and medical waste according to local guidelines.

Duration

Published distributor information and clinical marketing materials indicate that Eloquence Sub-Q typically provides long-lasting results, with effects generally lasting from approximately 6 to 18 months depending on the treatment area, injection technique, patient metabolism, lifestyle and age. The Crystal Pharmacy and Faces Consent describe visible effects lasting for up to 18 months in many cases. Maintenance or touch-up treatments may be carried out at the clinician\u2019s discretion once the effect begins to diminish.

Onset

Volumising and contouring effects are usually visible immediately after injection due to the physical presence of the hyaluronic acid gel. Final results become more apparent over several days as initial swelling subsides and the filler integrates with the surrounding tissues. A follow-up review after the initial healing period is recommended to assess results and determine whether refinement is needed.

Browse more Dermal filler \u2013 hyaluronic acid injectable

Top Treatments

Top Cities in the UK